Company intelligence / Profile preview

Altiris Therapeutics

Pittsburgh, Pennsylvania, USAaltiristherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Altiris Therapeutics is a clinical-stage biotechnology company specializing in the development of small molecule inhibitors for oncology indications. The company's research focuses on targeting the Bcl-2 family of proteins and the CXCR4/CXCL12 axis to overcome treatment resistance and prevent tumor metastasis. Its lead candidate, AT-101, is a pan-Bcl-2 inhibitor that has been evaluated in Phase 2 clinical trials for glioblastoma and other cancers. In 2021, Altiris was acquired by Vivesto (formerly Oasmia Pharmaceutical) to expand its portfolio of cancer therapies. The company's technology originated from research conducted at the University of Pittsburgh.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

MSX-122

Partnerships

University of Pittsburgh

Beyond the preview

Go deeper on Altiris Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altiris Therapeutics.